10x Genomics Q2 2026 Results: Flat Core Revenue and Persistent Losses Keep Bearish Thesis Intact

What happened

10x Genomics reported Q2 2026 results, with products and services revenue tracking roughly flat year-over-year, continuing the stagnation observed through late 2025. Instrument sales remained a significant drag, likely down over 30% as academic capital budgets stayed tight, while spatial consumables growth decelerated from high teens to low double digits. Operating losses narrowed only modestly as cost cuts were offset by declining gross margins ex‑settlements, and the company still relied on non‑recurring IP royalty streams to generate positive cash flow. Management’s forward commentary offered little hope of a near‑term inflection, reiterating that the first half of 2026 would resemble the second half of 2025. The report aligns with the thesis that TXG’s core business is not growing organically and that the equity multiple remains unsupported by sustainable earnings power.

Implication

The Q2 2026 release confirms that the bearish drivers identified in our master report are still playing out. Organic product and services revenue shows no meaningful growth, with instrument sales under >30% pressure and spatial consumables growth cooling. The company continues to depend on one‑off IP settlements and royalty streams to report positive cash flow and narrow losses, while underlying gross margins drift lower as mix shifts. With management guiding for continued flat‑to‑low‑single‑digit growth and NIH funding risk still unquantified, the risk‑reward remains unfavorable above $19. Investors should use any strength toward $22 to trim, and only consider re‑entry near $14 if a clear path to sustainable profitability emerges. The next catalyst will be whether the Scale Biosciences integration can genuinely revive single‑cell demand, but early signals are absent.

Thesis delta

The Q2 2026 results do not alter the POTENTIAL SELL rating. Core revenue weakness and margin reliance on litigation proceeds persist exactly as projected. No upgrade triggers have materialized; the thesis remains firmly bearish.